Kiah Bio’s platform transforms Nicotiana benthamiana into a high‑performance biological factory, enabling rapid, flexible, and cost‑effective production of complex biopharmaceuticals. Our proprietary vertical hydroponic system, combined with advanced transient expression technology, allows us to deliver high‑purity biologics in a fraction of the time required by traditional systems.

​

Controlled Plant Cultivation  
Plants are grown in a tightly regulated environment using high‑intensity vertical hydroponic systems. This ensures consistent biomass, predictable protein expression, and year‑round production capacity.

​

Precision Delivery  

Using a recombinant gene carried by Agrobacterium tumefaciens, we introduce the instructions needed for the plant to produce the target protein. Our proprietary infiltration technology enables rapid, transient expression without altering the plant’s genome or producing genetically modified seeds

​

Rapid Protein Expression  
Over several days, the plant’s cellular machinery produces the desired recombinant protein at high yield. Our unique plant variety and cultivation system significantly enhance expression efficiency and protein quality.

​

Harvesting and Biomass Processing  
Once expression reaches its peak, the leaves are harvested and processed. The biomass is homogenised and clarified to isolate the protein‑rich extract while removing plant material and impurities.

​

Purification and Downstream Processing  
Industry‑standard purification methods—such as filtration, chromatography, and polishing—are applied to achieve high‑purity biologics suitable for research, diagnostic, or therapeutic applications.

​

Quality Testing and Characterisation  
Each product undergoes rigorous analytical validation, including identity, purity, potency, stability, and safety assessments aligned with biopharmaceutical quality expectations.

​

Scale‑Up and Manufacturing Readiness  
The platform is designed for rapid scale‑up, enabling efficient transition from early development to pilot‑scale and commercial‑ready manufacturing. This supports the delivery of affordable, high‑quality biologics to domestic and emerging global markets.